- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05223725
Gene Therapy for Post-Operative Atrial Fibrillation (AFGT01)
October 11, 2023 updated by: Kevin Donahue
AdKCNH2-G628S Gene Therapy for Post-Operative Atrial Fibrillation
This clinical trial will have 2 components: a brief dose-ranging study and a randomized comparison of 2 doses of AdKCNH2-G628S with control cardiac surgery patients.
The study will assess safety of the intervention in a population at increased risk for post-operative atrial fibrillation.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Post-operative AF (POAF) is a specific form of AF occurring in the days after cardiothoracic surgery.
A unique element of POAF is the limited duration of risk, which peaks 3 days and dissipates 10 days after surgery.
We propose gene therapy for POAF.
Our hypothesis is that counteracting AF-related electrical remodeling will disrupt the reentrant electrical circuits integral to maintaining AF.
We have extensive preclinical data showing safety and efficacy of adenoviral gene transfer using the gene mutation KNCH2-G628S.
When delivered to the atria using adenoviruses and a novel gene painting technique, KCNH2-G628S effectively and specifically prolongs atrial action potential and prevents development of AF for the 10-14-day duration of post-operative AF risk.
This clinical trial will have 2 components: a brief dose-ranging study and a randomized comparison of 2 doses of AdKCNH2-G628S with control cardiac surgery patients.
Study Type
Interventional
Enrollment (Estimated)
78
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kevin Donahue, MD
- Phone Number: 508-421-1538
- Email: kevin.donahue@umassmed.edu
Study Contact Backup
- Name: Taylor Orwig
- Email: taylor.orwig@umassmed.edu
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- Recruiting
- UMass Memorial Hospital
-
Contact:
- Kevin Donahue, MD
- Phone Number: 508-421-1538
- Email: kevin.donahue@umassmed.edu
-
Contact:
- Taylor Orwig
- Email: taylor.orwig@umassmed.edu
-
Principal Investigator:
- David McManus, MD
-
Principal Investigator:
- Kevin Donahue, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion:
- Elective valve surgery (alone or with coronary artery bypass grafting surgery) and one of the risk factors listed below, or elective coronary artery bypass grafting surgery with two of the risk factors listed below.
Risk factors:
- age greater than 70,
- increased left atrial size (> 4 cm left atrial diameter or LA volume index > 35 on echocardiogram).
- obesity (body mass index > 30)
history of:
- paroxysmal AF
- hypertension
- chronic pulmonary disease
- diabetes mellitus
- clinical heart failure
- rheumatic heart disease
Exclusion:
- persistent or permanent AF
- QTc > 475 on pre-op ECG or any time in last year (unless due to QT prolonging drug that was stopped > 5 half-lives before surgery with verification of QT normalization after discontinuing drug)
- QTc prolonging drug use (unless stopped > 5 half-lives prior to surgery)
- Any antiarrhythmic drug use in last year (inclusive of Vaughan Williams class I and III drugs, not including β-blocker or calcium channel blocker drugs)
- Any history of inherited arrhythmia syndrome
- Any prior or current sustained ventricular arrhythmias
- Any prior or current clinically significant bradyarrhythmias unless already treated with pacemaker and ventricular pacing <20% (to reliable measure QT interval during the study)
- Any prior gene therapy
- Left ventricular ejection fraction (LVEF) < 35%
- Prior open chest surgery
- History of or current malignancy, unless documented to be cured
- History of or current chemotherapy, radiotherapy, or other immunosuppressive therapy within the past 30 days. Corticosteroid treatment may be permitted at the discretion of the Primary Investigator
- History of infection with human immunodeficiency virus (HIV), hepatitis A, B, or C, or tuberculosis
- Immunizations of any kind in the month prior to surgery
- Underlying defect in immune function or history of multiple or severe life-threatening infections
- Significant liver disease (active hepatitis, AST or ALT greater than twice the upper limit of normal, prior or current liver failure with Pugh-Child category A-C disease)
- Significant renal disease (GFR less than 30)
- Current pregnancy
- Childbearing potential unless participant agrees to prevent pregnancy prior to and for at least 3 months after virus delivery 10
- Any condition that limits life to < 12 months other than the condition to be treated with the planned surgery
- Participation in any other clinical trial within 30 days of surgery
- Incarcerated persons
- Individuals under the age of 18 years
- Unwillingness to undergo the study interventions and follow-up as outlined in the schedule of events
- Ongoing medical or other condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study
- Lack of capacity to provide participant's own informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dose escalation
initial phase, increasing dose
|
adenovirus containing the transgene KCNH2-G628S
|
Experimental: low dose
second phase, fixed dose 5x10(11) vp
|
adenovirus containing the transgene KCNH2-G628S
|
Experimental: high dose
second phase, fixed dose 2x10(12) vp
|
adenovirus containing the transgene KCNH2-G628S
|
No Intervention: control
second phase, blinded, randomized with no intervention delivered but with testing and monitoring.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of patients having a post-operative complication relative to controls
Time Frame: 3 months
|
proportion of patients having a post-operative complication relative to controls
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of patients having post-operative atrial fibrillation
Time Frame: 1 month
|
proportion of patients having post-operative atrial fibrillation
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kevin Donahue, MD, University of Massachusetts Chan Medical School
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kikuchi K, McDonald AD, Sasano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation. 2005 Jan 25;111(3):264-70. doi: 10.1161/01.CIR.0000153338.47507.83. Epub 2005 Jan 10.
- Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010 Jun 1;121(21):2263-70. doi: 10.1161/CIRCULATIONAHA.109.911156. Epub 2010 May 17.
- Liu Z, Hutt JA, Rajeshkumar B, Azuma Y, Duan KL, Donahue JK. Preclinical efficacy and safety of KCNH2-G628S gene therapy for postoperative atrial fibrillation. J Thorac Cardiovasc Surg. 2017 Nov;154(5):1644-1651.e8. doi: 10.1016/j.jtcvs.2017.05.052. Epub 2017 May 23.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2023
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
August 1, 2026
Study Registration Dates
First Submitted
January 24, 2022
First Submitted That Met QC Criteria
January 24, 2022
First Posted (Actual)
February 4, 2022
Study Record Updates
Last Update Posted (Actual)
October 13, 2023
Last Update Submitted That Met QC Criteria
October 11, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WIRB1333791
- 4R33HL158541 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data from the clinical trial will be made available to the scientific community and the general public in the following ways:
- As soon as final data are complete, verified and analyzed, manuscripts will be written and submitted to scientific journals with the highest possible impact factor to achieve the widest possible dissemination within the scientific community.
- Presentations at scientific meetings within the disciplines of cardiac surgery, cardiology, cardiac electrophysiology and gene therapy will further disseminate the research information gained as a result of the proposed studies.
- The research data will be uploaded to an openly available research website maintained by UMass for review and use by the scientific community.
- The research results will be uploaded to clinicaltrials.gov.
- Press releases, summaries of research findings and interviews with investigators will be released to the general public to publicize the information gained in the proposed research.
IPD Sharing Time Frame
as per plan description
IPD Sharing Access Criteria
as per plan description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium